The Ainslie Lab is pleased to announce that we have received Eshelman Institute for Innovation Tier 1 funding to develop long-acting HIV therapies.
June 15, 2016
The Ainslie Lab is pleased to announce that we have received Eshelman Institute for Innovation Tier 1 funding to develop long-acting HIV therapies.
The Ainslie Lab is happy to announce we were just awarded a collaborative NIH R01 with Lead Investigator Dr. Shawn Hingtgen.
June 2, 2016
The Ainslie Lab is pleased to announce we were just awarded a collaborative NIH R01 with Lead Investigator Dr. Shawn Hingtgen (UNC Eshelman School of Pharmacy). The award is titled: “Nanofiber matrices to improve neural stem cell-mediated cancer therapy”. We … Read more
The Ainslie Lab is pleased to announce they were just award nearly $6 million by the NIH to study host-directed treatments for drug resistant bacterial infections.
April 22, 2016
The Ainslie Lab is pleased to announce they were just award nearly $6 million by the NIH to study host-directed treatments for drug resistant bacterial infections. This grant would not be possible without Co-PI Dr. Bruce Blough at RTI International, … Read more